Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.56 |
| ▸ | GABRP | O00591 | 1/20 | 0.56 |
| ▸ | GABRD | O14764 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.56 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.56 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.56 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.56 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28534140 | 0.98 | BLM (0.56) | TSHRLMNAKMT2ATHRBBLM | |
| SCHEMBL17633867 | 0.93 | NFKB1 (0.58) | TSHRLMNAKMT2ATHRBBLM | |
| SCHEMBL11493068 | 0.91 | LMNA (0.60) | TSHRLMNAKMT2ATHRBBLM | |
| SCHEMBL756105 | 0.87 | TSHR (0.71) | TSHRLMNAKMT2ATHRBBLM | |
| SCHEMBL2550571 | 0.85 | — | — | |
| SCHEMBL31241576 | 0.85 | TSHR (0.68) | TSHRLMNAKMT2ATHRBBLM | |
| SCHEMBL98206 | 0.83 | TSHR (0.60) | TSHRLMNAKMT2ATHRBBLM | |
| Hydrochloric Acid SCHEMBL28113982 | 0.83 | LMNA (0.70) | TSHRLMNAKMT2ATHRBBLM | |
| SCHEMBL6866613 | 0.82 | LMNA (0.78) | TSHRLMNAKMT2ATHRBBLM | |
| SCHEMBL9261329 | 0.82 | LMNA (0.74) | TSHRLMNAKMT2ATHRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109477840-A | For non-destructively determining the method and system of Fowl Sex in ovum | 因欧沃私人有限责任公司 | 2019-03-15 | — | — | CN | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| US-11771665-B2 | Compositions, methods of treatment, and containers including compositions | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| EP-4157247-A1 | ANTI-VIRAL THERAPY | Novabiotics Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
| US-11369568-B2 | Microparticles comprising a sulphur-containing compound | NOVABIOTICS LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| WO-2021240145-A1 | ANTI-VIRAL THERAPY | NOVABIOTICS LIMITED (GB) | 2021-12-02 | — | — | WO | disclosed |
| US-20210299019-A1 | METHODS FOR TREATING HYPERPIGMENTATION AND COMPOSITIONS FOR SAME | CHEMISTRYRX (US) | 2021-09-30 | — | — | US | disclosed |
| US-10905660-B2 | Microparticles | NOVABIOTICS LIMITED (GB) | 2021-02-02 | — | — | US | disclosed |
| US-20190175501-A1 | MICROPARTICLES COMPRISING A SULPHUR-ONTAINING COMPOUND | NOVABIOTICS LIMITED (GB) | 2019-06-13 | — | — | US | disclosed |
| EP-3463325-A1 | MICROPARTICLES COMPRISING A SULPHUR-CONTAINING COMPOUND | Novabiotics Limited (GB) | 2019-04-10 | — | — | EP | disclosed |
| WO-2016198842-A1 | AN AMINO THIOL FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY THE BACTERIUM MYCOBACTERIUM SPP. | NOVABIOTICS LIMITED (GB) | 2016-12-15 | — | — | WO | disclosed |
| US-20160102052-A1 | Use of Cysteamine in Treating Infections caused by Yeasts/Moulds | NOVABIOTICS LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| US-4394520-A | SKIN DISORDERS | SOCIETE ANONYME DITE: L'OREAL (FR) | 1983-07-19 | — | — | US | disclosed |
| US-4204064-A | FOR TREATMENT OF SKIN OR SCALP | L'OREAL (FR) | 1980-05-20 | — | — | US | disclosed |
| US-4139635-A | Cysteamine derivatives for oral treatment of seborrhea | L'OREAL (FR) | 1979-02-13 | — | — | US | disclosed |
| US-4085217-A | DERIVATIVES OF CYSTEINE OR CYSTEAMINE | L'OREAL (FR) | 1978-04-18 | — | — | US | disclosed |
| US-4035492-A | Oral treatment of seborrhea with cysteamine derivatives | L'OREAL (FR) | 1977-07-12 | — | — | US | disclosed |
| US-3976781-A | SULFUR CONTAINING AMINES | L'OREAL (FR) | 1976-08-24 | — | — | US | disclosed |
| US-3950542-A | Cysteamine derivatives for oral treatment of seborrhea | L'OREAL (FR) | 1976-04-13 | — | — | US | disclosed |